Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Antimicrob Agents Chemother ; 66(11): e0095122, 2022 11 15.
Article in English | MEDLINE | ID: mdl-36314868

ABSTRACT

LHF-535 is a small-molecule antiviral currently under development as a therapeutic option to treat Lassa fever and other viral hemorrhagic fevers of arenavirus origin. The human safety and pharmacokinetics of LHF-535 were evaluated in two phase 1 trials in healthy volunteers. The first study was a double-blind, single ascending dose trial that evaluated weight-based oral doses ranging from 0.3 mg/kg in the first cohort to 40 mg/kg in the last cohort. The second study was a double-blind, multiple ascending dose trial that evaluated a 14-day oral dosing regimen, with three sequential cohorts receiving fixed doses of 450, 900, or 1,125 mg per day; the third cohort (1,125 mg/day) received a higher (loading) dose of 2,250 mg for the first dose. Each cohort in both studies consisted of eight participants randomized to either placebo (n = 2) or LHF-535 (n = 6). LHF-535 was well tolerated in both studies. Treatment-emergent adverse events were more frequent in placebo recipients than in LHF-535 recipients in both studies. LHF-535 exhibited rapid absorption, a long half-life, and exposures predicted to suppress viral replication.


Subject(s)
Hemorrhagic Fevers, Viral , Lassa Fever , Humans , Adult , Lassa Fever/drug therapy , Antiviral Agents/adverse effects , Antiviral Agents/pharmacokinetics , Double-Blind Method , Healthy Volunteers , Dose-Response Relationship, Drug
2.
N Engl J Med ; 373(4): 339-48, 2015 Jul 23.
Article in English | MEDLINE | ID: mdl-26200980

ABSTRACT

BACKGROUND: AVI-7288 is a phosphorodiamidate morpholino oligomer with positive charges that targets the viral messenger RNA that encodes Marburg virus (MARV) nucleoprotein. Its safety in humans is undetermined. METHODS: We assessed the efficacy of AVI-7288 in a series of studies involving a lethal challenge with MARV in nonhuman primates. The safety of AVI-7288 was evaluated in a randomized, multiple-ascending-dose study in which 40 healthy humans (8 humans per dose group) received 14 once-daily infusions of AVI-7288 (1 mg, 4 mg, 8 mg, 12 mg, or 16 mg per kilogram of body weight) or placebo, in a 3:1 ratio. We estimated the protective dose in humans by comparing pharmacokinetic variables in infected nonhuman primates, uninfected nonhuman primates, and uninfected humans. RESULTS: Survival in infected nonhuman primates was dose-dependent, with survival rates of 0%, 30%, 59%, 87%, 100%, and 100% among monkeys treated with 0 mg, 3.75 mg, 7.5 mg, 15 mg, 20 mg, and 30 mg of AVI-7288 per kilogram, respectively (P<0.001 with the use of the log-rank test for the comparison of survival across groups). No safety concern was identified at doses up to 16 mg per kilogram per day in humans. No serious adverse events were reported. Drug exposure (the area under the curve) was dose-dependent in both nonhuman primates and humans; drug clearance was independent of dose but was higher in nonhuman primates than in humans. The protective dose in humans was initially estimated, on the basis of exposure, to be 9.6 mg per kilogram per day (95% confidence interval, 6.6 to 12.5) for 14 days. Monte Carlo simulations supported a dose of 11 mg per kilogram per day to match the geometric mean protective exposure in nonhuman primates. CONCLUSIONS: This study shows that, on the basis of efficacy in nonhuman primates and pharmacokinetic data in humans, AVI-7288 has potential as postexposure prophylaxis for MARV infection in humans. (Funded by the Department of Defense; ClinicalTrials.gov number, NCT01566877.).


Subject(s)
Antiviral Agents/administration & dosage , Marburg Virus Disease/drug therapy , Marburgvirus , Morpholinos/administration & dosage , Animals , Antiviral Agents/adverse effects , Antiviral Agents/pharmacokinetics , Disease Models, Animal , Dose-Response Relationship, Drug , Humans , Kaplan-Meier Estimate , Macaca fascicularis , Marburg Virus Disease/mortality , Marburgvirus/genetics , Morpholinos/adverse effects , Morpholinos/pharmacokinetics , RNA, Messenger , RNA, Viral
3.
mBio ; 6(1)2015 Feb 10.
Article in English | MEDLINE | ID: mdl-25670780

ABSTRACT

UNLABELLED: Ebola viruses (EBOV) cause severe disease in humans and nonhuman primates with high mortality rates and continue to emerge in new geographic locations, including several countries in West Africa, the site of a large ongoing outbreak. Phosphorodiamidate morpholino oligomers (PMOs) are synthetic antisense molecules that are able to target mRNAs in a sequence-specific fashion and suppress translation through steric hindrance. We previously showed that the use of PMOs targeting a combination of VP35 and VP24 protected rhesus monkeys from lethal EBOV infection. Surprisingly, the present study revealed that a PMOplus compound targeting VP24 alone was sufficient to confer protection from lethal EBOV infection but that a PMOplus targeting VP35 alone resulted in no protection. This study further substantiates recent data demonstrating that VP24 may be a key virulence factor encoded by EBOV and suggests that VP24 is a promising target for the development of effective anti-EBOV countermeasures. IMPORTANCE: Several West African countries are currently being ravaged by an outbreak of Ebola virus (EBOV) that has become a major epidemic affecting not only these African countries but also Europe and the United States. A better understanding of the mechanism of virulence of EBOV is important for the development of effective treatments, as no licensed treatments or vaccines for EBOV disease are currently available. This study of phosphorodiamidate morpholino oligomers (PMOs) targeting the mRNAs of two different EBOV proteins, alone and in combination, demonstrated that targeting a single protein was effective at conferring a significant survival benefit in an EBOV lethal primate model. Future development of PMOs with efficacy against EBOV will be simplified if only one PMO is required instead of a combination, particularly in terms of regulatory approval.


Subject(s)
Ebolavirus/genetics , Hemorrhagic Fever, Ebola/prevention & control , Morpholinos/administration & dosage , Viral Proteins/genetics , Animals , Ebolavirus/drug effects , Ebolavirus/metabolism , Hemorrhagic Fever, Ebola/virology , Humans , Macaca mulatta , Viral Proteins/antagonists & inhibitors , Viral Proteins/metabolism
4.
Antimicrob Agents Chemother ; 58(11): 6639-47, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25155593

ABSTRACT

Two identical single-ascending-dose studies evaluated the safety and pharmacokinetics (PK) of AVI-6002 and AVI-6003, two experimental combinations of phosphorodiamidate morpholino oligomers with positive charges (PMOplus) that target viral mRNA encoding Ebola virus and Marburg virus proteins, respectively. Both AVI-6002 and AVI-6003 were found to suppress disease in virus-infected nonhuman primates in previous studies. AVI-6002 (a combination of AVI-7537 and AVI-7539) or AVI-6003 (a combination of AVI-7287 and AVI-7288) were administered as sequential intravenous (i.v.) infusions of a 1:1 fixed dose ratio of the two subcomponents. In each study, 30 healthy male and female subjects between 18 and 50 years of age were enrolled in six-dose escalation cohorts of five subjects each and received a single i.v. infusion of active study drug (0.005, 0.05, 0.5, 1.5, 3, and 4.5 mg/kg per component) or placebo in a 4:1 ratio. Both AVI-6002 and AVI-6003 were safe and well tolerated at the doses studied. A maximum tolerated dose was not observed in either study. The four chemically similar PMOplus components exhibited generally similar PK profiles. The mean peak plasma concentration and area under the concentration-time curve values of the four components exhibited dose-proportional PK. The estimated plasma half-life of all four components was 2 to 5 h. The safety of the two combinations and the PK of the four components were similar, regardless of the target RNA sequence.


Subject(s)
Hemorrhagic Fever, Ebola/drug therapy , Marburg Virus Disease/drug therapy , Morpholinos/pharmacokinetics , Adult , Animals , Area Under Curve , Double-Blind Method , Ebolavirus/drug effects , Ebolavirus/genetics , Female , Hemorrhagic Fever, Ebola/virology , Humans , Infusions, Intravenous , Male , Marburg Virus Disease/virology , Marburgvirus/drug effects , Marburgvirus/genetics , Middle Aged , Morpholinos/adverse effects , Morpholinos/blood , Placebos , Young Adult
5.
Sex Transm Dis ; 38(5): 442-4, 2011 May.
Article in English | MEDLINE | ID: mdl-21124258

ABSTRACT

With the rising incidence and prevalence of syphilis, meningovascular syphilis and other forms of neurosyphilis have reappeared, particularly among persons infected with human immunodeficiency virus. We present a patient with meningovascular syphilis leading to stroke after treatment with penicillin and antiretroviral therapy.


Subject(s)
HIV Infections/complications , Neurosyphilis/complications , Stroke/complications , Anti-Bacterial Agents/therapeutic use , Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV Infections/virology , HIV-1/drug effects , Humans , Male , Middle Aged , Neurosyphilis/drug therapy , Neurosyphilis/microbiology , Penicillins/therapeutic use , Treponema pallidum/drug effects
6.
AIDS Res Hum Retroviruses ; 26(8): 933-42, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20666584

ABSTRACT

The recombinant vaccine, tgAAC09, based on an adeno-associated virus serotype 2 (AAV2) vector encoding HIV-1 subtype C Gag, protease, and part of reverse transcriptase, induced robust T cell and antibody responses in nonhuman primates. In a previous phase I study in 80 healthy HIV-seronegative European and Indian adults, the vaccine was generally safe, well tolerated, and modestly immunogenic when administered once at doses up to 3 x 10(11) DRP. This phase II double-blind, randomized, placebo-controlled trial tested two administrations and a higher dosage of tgAAC009. Ninety-one healthy HIV-seronegative adults from three African countries were given one of three dosage levels of tgAAC09 (3 x 10(10), 3 x 10(11), or 3 x 10(12) DRP) intramuscularly, either at a 6- or 12-month interval; follow-up was 18 months. Overall, 65% and 57% of vaccine recipients experienced local and systemic signs and symptoms, respectively, most being mild. Frequency and severity were not dose related and were similar to those in placebo recipients. No vaccine-related serious adverse events were reported. Overall, HIV-specific T cell responses were detected by IFN-gamma ELISPOT in 17/69 (25%) vaccine recipients with 38% (10/26) responders in the highest dosage group. The response rate improved significantly with boosting at 6, but not 12 months, in the 3 x 10(11) and 3 x 10(12) dosage groups only. Neutralizing antibody titers to the AAV2 did not alter the frequency of immune responses to HIV. Two doses of tgAAC09 were well tolerated at the dosage levels given. Fewer than half the recipients of the highest vaccine dosage, 3 x 10(12) DRP, had T cell responses to HIV.


Subject(s)
AIDS Vaccines/administration & dosage , HIV Infections/prevention & control , AIDS Vaccines/adverse effects , AIDS Vaccines/immunology , Adult , Antibodies, Neutralizing/blood , Antibody Formation , Dependovirus/immunology , Double-Blind Method , Female , Genetic Vectors/immunology , HIV Antibodies/blood , HIV Infections/immunology , HIV-1/immunology , Humans , Immunization Schedule , Male , Middle Aged , T-Lymphocytes/immunology , T-Lymphocytes/virology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/adverse effects , Vaccines, Synthetic/immunology , Young Adult
7.
J Rheumatol ; 37(5): 1042-8, 2010 May.
Article in English | MEDLINE | ID: mdl-20231202

ABSTRACT

OBJECTIVE: To assess the validity, responsiveness, and reliability of single-joint outcome measures for determining target joint (TJ) response in patients with inflammatory arthritis. METHODS: Patient-reported outcomes (PRO), consisting of responses to single questions about TJ global status on a 100-mm visual analog scale (VAS; TJ global score), function on a 100-mm VAS (TJ function score), and pain on a 5-point Likert scale (TJ pain score) were piloted in 66 inflammatory arthritis subjects in a phase 1/2 clinical study of an intraarticular gene transfer agent and compared to physical examination measures (TJ swelling, TJ tenderness) and validated function questionnaires (Disabilities of the Arm, Shoulder and Hand scale, Rheumatoid Arthritis Outcome Score, and the Health Assessment Questionnaire). Construct validity was assessed by evaluating the correlation between the single-joint outcome measures and validated function questionnaires using Spearman's rank correlation. Responsiveness or sensitivity to change was assessed through calculating effect size and standardized response means (SRM). Reliability of physical examination measures was assessed by determining interobserver agreement. RESULTS: The single-joint PRO were highly correlated with each other and correlated well with validated functional measures. The TJ global score exhibited modest effect size and modest SRM that correlated well with the patient's assessment of response on a 100-mm VAS. Physical examination measures exhibited high interrater reliability, but correlated less well with validated functional measures and the patient's assessment of response. CONCLUSION: Single-joint PRO, particularly the TJ global score, are simple to administer and demonstrate construct validity and responsiveness in patients with inflammatory arthritis. (ClinicalTrials.gov identifier NCT00126724).


Subject(s)
Arthritis, Psoriatic/physiopathology , Arthritis, Rheumatoid/physiopathology , Joints/physiopathology , Patient Participation/methods , Activities of Daily Living , Adult , Aged , Disability Evaluation , Female , Health Status , Humans , Male , Middle Aged , Outcome Assessment, Health Care , Pain Measurement/standards , Physical Examination , Quality of Life , Reproducibility of Results , Sensitivity and Specificity , Severity of Illness Index , Surveys and Questionnaires/standards
8.
J Rheumatol ; 37(4): 692-703, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20032102

ABSTRACT

OBJECTIVE: To assess safety and clinical outcomes in patients with inflammatory arthritis after intraarticular (IA) injection of rAAV2-TNFR:Fc, a recombinant adeno-associated viral vector containing the human tumor necrosis factor (TNF) receptor-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) gene. METHODS: In this phase 1/2 randomized study, adults with persistent moderate or severe inflammation in a target joint, being treated with or without systemic anti-TNF therapy, received a single IA injection of either rAAV2-TNFR:Fc (1 x 10(11), 1 x 10(12), or 1 x 10(13) DNase-resistant particles/ml joint volume) or placebo, followed by open-label rAAV2-TNFR:Fc 12-30 weeks later, depending on when the target joint met predetermined criteria for reinjection. RESULTS: 127 subjects received the first injection of blinded study drug; 95 subjects received open-label rAAV2-TNFR:Fc. Administration site reactions, consisting of transient mild to moderate increases in tenderness and swelling of the injected joint, occurred after 23/191 (12%) rAAV2-TNFR:Fc injections and were dose-dependent. Rates of other adverse events were not dose-dependent. Notable serious adverse events (SAE) included culture-negative septic arthritis in a subject receiving leflunomide and fatal disseminated histoplasmosis considered unrelated to rAAV2-TNFR:Fc in a subject receiving adalimumab. In the phase 2 portion of the study, a 30% decrease in target joint global visual analog scale was observed in 21/50 (42%) rAAV2-TNFR:Fc subjects and 3/16 (19%) placebo subjects 12 weeks after first injection (p = 0.14). CONCLUSION: IA rAAV2-TNFR:Fc resulted in administration site reactions after 12% of injections. A fatal SAE, disseminated histoplasmosis, was considered not related to study agent. Patient-reported outcome measures of clinical response showed greater improvement in treated patients than placebo patients.


Subject(s)
Arthritis/therapy , Genetic Therapy/adverse effects , Immunoglobulin G/adverse effects , Receptors, Tumor Necrosis Factor/genetics , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/genetics , Adenoviridae , Adult , Antirheumatic Agents/adverse effects , Antirheumatic Agents/immunology , Arthritis/immunology , Dose-Response Relationship, Drug , Double-Blind Method , Enzyme-Linked Immunosorbent Assay , Female , Genetic Vectors , Humans , Immunity, Cellular , Immunoglobulin G/genetics , Immunoglobulin G/immunology , Injections, Intra-Articular , Male , Patient Selection , Receptors, Tumor Necrosis Factor/immunology , Receptors, Tumor Necrosis Factor/therapeutic use , Treatment Outcome
9.
J Rheumatol ; 36(9): 2092-6, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19738219

ABSTRACT

The need to develop validated outcome measures to assess response to therapies in single joints has been recognized. In 2004, a task force was established to assess established and novel outcome measures in accordance with the OMERACT filter (truth, discrimination, and feasibility) for single joint assessment. This report describes the proceedings of the single joint assessment special interest group (SIG) at OMERACT 9, including an updated literature review of imaging of the knee joints, with a focus on the extent to which these modalities fulfill the OMERACT filter. A series of studies are reported that examine patient reported, clinical examination, and imaging outcomes in therapeutic studies in knee arthritis. A summary of discussions from the meeting are presented that raise many of the ongoing challenges in establishing appropriate domains to evaluate a range of conditions and potential therapeutic interventions. Because of emerging drug candidates and modalities targeting individual joints, the ongoing work of this SIG is providing the evidence base that can be used to establish a core domain set to incorporate as outcomes in future studies.


Subject(s)
Arthritis/therapy , Knee Joint/physiopathology , Outcome Assessment, Health Care , Arthritis/pathology , Arthritis/physiopathology , Humans , Knee Joint/pathology , Reproducibility of Results
10.
AIDS Res Hum Retroviruses ; 24(6): 873-80, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18544020

ABSTRACT

A novel prophylactic AIDS vaccine candidate, consisting of single-stranded DNA for HIV-1 subtype C gag, protease, and part of reverse transcriptase genes, enclosed within a recombinant adeno-associated virus serotype-2 protein capsid (tgAAC09) induced T cell responses and antibodies in nonhuman primates. In this randomized, dose escalation phase I trial, HIV-uninfected healthy volunteers (50 in Europe, 30 in India) received a single intramuscular injection of tgAAC09 at 3 x 10(9) DNase resistant particles (DRP) (n = 16), 3 x 10(10) DRP (n = 23), 3 x 10(11) DRP (n = 25), or placebo (n = 16). Twenty-one participants in Europe received a second (boost) dose of 3 x 10(11) DRP tgAAC09 or placebo at least 24 weeks after the first injection. The vaccine was safe and well-tolerated after initial and boost vaccination. Local and systemic reactogenicity was experienced by 13-25% of participants and was not dose related. No vaccine-related serious adverse events were reported. Modest HIV-specific T cell responses were detected in 7/64 vaccinees (40-385 SFC/10(6) PBMC), with 16% (4/25) responders in the highest dose group. All responses were to Gag epitopes. tgAAC09 appears to be safe, well-tolerated, and modestly immunogenic. Further evaluation of higher doses of tgAAC09 and boost injections is ongoing in Africa.


Subject(s)
AIDS Vaccines/administration & dosage , HIV-1/immunology , T-Lymphocytes/immunology , Vaccines, Virosome/administration & dosage , gag Gene Products, Human Immunodeficiency Virus/immunology , AIDS Vaccines/adverse effects , Adolescent , Adult , Antibody Formation , Capsid/immunology , DNA, Viral/administration & dosage , Dependovirus/immunology , Double-Blind Method , Female , HIV Infections/prevention & control , Humans , Immunity, Cellular , Immunization, Secondary , Injections, Intramuscular , Interferon-gamma/blood , Male , Middle Aged , Neutralization Tests , Vaccines, DNA/administration & dosage , Vaccines, DNA/adverse effects , Vaccines, DNA/immunology , Vaccines, Virosome/adverse effects
11.
Hum Gene Ther ; 18(8): 726-32, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17685853

ABSTRACT

Previous studies have demonstrated that delivery of a recombinant adeno-associated virus (AAV) vector encoding the complete human cystic fibrosis transmembrane regulator (CFTR) cDNA (tgAAVCF) to the nose, sinus, and lungs of subjects with cystic fibrosis (CF) was safe and well tolerated. In a small randomized, double-blind study of three doses of aerosolized tgAAVCF or placebo at 30-day intervals, encouraging but non-significant trends in pulmonary function and induced sputum interleukin 8 (IL-8) levels were seen at early time points. This larger study was conducted to verify these trends. One hundred and two subjects aged 12 years and older with mild-to-moderate cystic fibrosis (forced expiratory flow in 1 sec [FEV1]:60% predicted) were randomized to two aerosolized doses of 1x10(13)DNase-resistant particles of tgAAVCF (n=51) or matching placebo (n=51) administered 30 days apart. Although tgAAVCF was well tolerated, the study did not meet its primary efficacy end point of statistically significant improvement in FEV1 30 days after initial administration of tgAAVCF compared with placebo. There were no significant differences in spirometric lung function over time, induced sputum biologic markers, or days of antibiotic use in either treatment group. Thus repeated doses of aerosolized tgAAVCF were safe and well tolerated, but did not result in significant improvement in lung function over time. Because gene transfer is the simplest, most basic way to correct the underlying genetic defect that leads to disease in CF, further research is warranted to develop an effective gene transfer agent for the treatment of CF.


Subject(s)
Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis/therapy , Dependovirus , Genetic Therapy , Administration, Inhalation , Adult , Child , Female , Humans , Male , Placebos
12.
Ann Occup Hyg ; 48(8): 673-81, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15507460

ABSTRACT

A study was conducted to assess health care worker exposure to tgAAVCF during the aerosolized administration of this experimental gene transfer agent in clinical trials for the treatment of cystic fibrosis (CF). tgAAVCF is a recombinant adeno-associated virus (AAV) genetically engineered to contain the human CF transmembrane conductance regulator cDNA. Study subjects included eight health care workers involved in the administration of tgAAVCF in a phase II study and 12 control health care workers who were involved with the treatment of CF patients, but not administration of the study drug. The exposure assessment entailed the determination of personal and area airborne tgAAVCF concentrations. In addition, serologic status of the health care workers was evaluated throughout the study for the presence of antibodies to AAV. A symptom survey was also completed by both the active and control health care workers. Air samples were analyzed by an infectivity assay (active vector) and a DNA polymerase chain reaction amplification procedure (vector DNA). Air monitoring was conducted during 13 tgAAVCF and seven placebo administrations. Active vector and vector particles were detected in four of 51 and 48 of 51 air samples collected during the administration of tgAAVCF, respectively. Based on the airborne vector particle concentration, the workers' exposure was estimated to be 0.0006% of the administered dose. At this level of exposure, the prevalence of symptoms was very low, the spectrum was similar in both study groups and did not result in any reported negative health effects.


Subject(s)
Cystic Fibrosis/therapy , Genetic Therapy/methods , Genetic Vectors/adverse effects , Inhalation Exposure/analysis , Occupational Exposure/analysis , Patient Care Team , Case-Control Studies , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Dependovirus/genetics , Dependovirus/isolation & purification , Genetic Vectors/administration & dosage , Humans , Nebulizers and Vaporizers
13.
Chest ; 125(2): 509-21, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14769732

ABSTRACT

STUDY OBJECTIVES: The primary objective was to determine the safety and tolerability of repeated doses of aerosolized adeno-associated serotype 2 vector containing cystic fibrosis transmembrane conductance regulator (CFTR) complementary DNA (cDNA) [tgAAVCF], an adeno-associated virus (AAV) vector encoding the complete human CFTR cDNA. Secondary objectives included evaluation of pulmonary function assessed by spirometry, lung abnormalities by high-resolution CT (HRCT), airway cytokines, vector shedding, serum neutralizing antibody to AAV serotype 2 (AAV2), and gene transfer and expression in a subset of subjects undergoing bronchoscopy with bronchial brushings. DESIGN: Randomized, double-blind, placebo-controlled, phase II trial. SETTING: Eight cystic fibrosis (CF) centers in the United States. SUBJECTS: CF patients with mild lung disease, defined as FEV(1) > or =60% predicted. INTERVENTIONS: Subjects were randomized to inhale three aerosolized doses of 1 x 10(13) deoxyribonuclease-resistant particles of tgAAVCF or matching placebo at 30-day intervals using the Pari LC Plus nebulizer (PARI; Richmond, VA). MEASUREMENTS AND RESULTS: Of 42 subjects randomized, 20 subjects received at least one dose of tgAAVCF and 17 subjects received placebo. No difference in the pattern of adverse events or laboratory abnormalities was noted between the two treatment groups. Improvements in induced-sputum interleukin-8 (p = 0.03) and FEV(1) (p = 0.04) were observed at day 14 and day 30, respectively, in the group receiving tgAAVCF when compared to those receiving placebo. No significant differences in HRCT scans were noted. Vector shedding in sputum was observed at low levels up to 90 days after the third dose of vector. All subjects receiving tgAAVCF exhibited an increase (by at least fourfold) in serum AAV2-neutralizing antibodies and detectable levels in BAL fluid from five of six treated subjects undergoing BAL. Gene transfer but not gene expression was detected in a subset of six tgAAVCF subjects who underwent bronchoscopy. CONCLUSIONS: Repeat doses of aerosolized tgAAVCF were safe and well tolerated, and resulted in encouraging trends in improvement in pulmonary function in patients with CF and mild lung disease.


Subject(s)
Cystic Fibrosis Transmembrane Conductance Regulator/administration & dosage , Cystic Fibrosis/therapy , Genetic Therapy/methods , Administration, Inhalation , Adolescent , Adult , Aerosols/administration & dosage , Analysis of Variance , Bronchoscopy , Child , Cystic Fibrosis/diagnosis , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Female , Gene Transfer Techniques , Humans , Male , Probability , Respiratory Function Tests , Risk Assessment , Severity of Illness Index , Statistics, Nonparametric , Treatment Outcome
14.
Hum Gene Ther ; 14(11): 1079-88, 2003 Jul 20.
Article in English | MEDLINE | ID: mdl-12885347

ABSTRACT

Recombinant adeno-associated serotype 2-based vectors (rAAV2) possess a number of theoretical advantages for cystic fibrosis (CF) gene therapy because they elicit little or no inflammatory response and generally result in stable expression. rAAV2 vectors expressing the cystic fibrosis transmembrane conductance regulator (CFTR) gene have previously been shown to mediate stable correction of the CF defect in CF bronchial epithelial cells and stable expression of CFTR in rabbit and nonhuman primate models. Here we report the results of the first trial initiated with rAAV in humans, a phase I study in 25 adult and adolescent CF patients with mild to moderate lung disease. Doses of the rAAV-CFTR vector (tgAAVCF) ranging from 3 x 10(1) to 1 x 10(9) replication units (RU), which is equivalent to approximately 6 x 10(4) to 2 x 10(12) DNase resistant particles (DRP), were administered to one side of the nose and to the superior segment of the lower lobe of the right lung. Several adverse events were noted prior to and/or after vector delivery, but most of them appeared to be related to the endogenous CF lung disease or a result of the bronchoscopic procedures. Only one of the serious events was judged to be possibly vector-related (based on temporal association), and this event was a pulmonary exacerbation very similar to several others experienced by the same subject in the three months preceding vector delivery. Vector shedding was minimal throughout the study, and serum-neutralizing antibodies were detected after vector delivery to subjects in the highest dosage cohorts. Gene transfer as measured by DNA polymerase chain reaction (PCR) was not observed until cohort 10 in nasal and bronchial epithelia. Sporadic low-level copy numbers suggested gene transfer of anywhere from 0.002 copies per cell up to 0.5 copies per cell was possible; however, DNA PCR was positive in lungs prior to direct dosing suggesting aspiration from the nasal dosing. These data indicate the need for continued evaluation of rAAV-CFTR vectors in additional clinical trials.


Subject(s)
Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis/therapy , Dependovirus/genetics , Genetic Vectors/toxicity , Administration, Intranasal , Adolescent , Adult , Antibodies, Viral/blood , Bronchi , Cystic Fibrosis/diagnosis , Cystic Fibrosis/immunology , DNA, Recombinant/genetics , DNA, Viral/analysis , Dependovirus/immunology , Enzyme-Linked Immunosorbent Assay , Genetic Vectors/administration & dosage , Humans , Interleukins/biosynthesis , Male , Viremia/diagnosis , Virus Shedding
15.
Head Neck ; 24(7): 661-9, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12112540

ABSTRACT

BACKGROUND: The anti-cancer gene, E1A, can be complexed to a lipid carrier, DC-Cholesterol:DOPE, to form tgDCC-E1A, which can be injected directly into tumors. METHODS: Twenty-four patients with recurrent, unresectable, head and neck cancer were treated with intratumoral injections of tgDCC-E1A over 8 weeks. Tumor response was assessed using CT scans. Time to progression and overall survival were calculated. RESULTS: Intratumoral tgDCC-E1A was well tolerated in all patients. No significant toxicities related to tgDCC-E1A were reported. One patient (4.2%) had a complete response, two patients (8.3%) had minor response, and seven patients (29.2%) had stable disease by two-dimensional cross-products on blinded CT scans. The median time to progression was 8.6 weeks (range, 3.3-43.7 weeks), and median survival was 4.6 months (range, 1.3-15.6 months). CONCLUSIONS: Intratumoral injections of tgDCC-E1A were safe and well tolerated. Modest tumor response was observed. Further development of tgDCC-E1A is warranted in combination with other treatment modalities.


Subject(s)
Adenovirus E1A Proteins/administration & dosage , Carcinoma, Squamous Cell/therapy , Cholesterol/analogs & derivatives , Head and Neck Neoplasms/therapy , Neoplasm Recurrence, Local/therapy , Adenovirus E1A Proteins/metabolism , Adult , Aged , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/mortality , Drug Carriers , Female , Gene Expression , Gene Transfer Techniques , Head and Neck Neoplasms/genetics , Head and Neck Neoplasms/mortality , Humans , Immunohistochemistry , Injections, Intralesional , Liposomes , Male , Middle Aged , Neoplasm Recurrence, Local/genetics , Neoplasm Recurrence, Local/mortality , Reverse Transcriptase Polymerase Chain Reaction
16.
J Am Geriatr Soc ; 50(4): 603-7, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11982658

ABSTRACT

OBJECTIVES: To determine the effect of antiretroviral therapy (ART) on the immunological and virological outcomes of older human immunodeficiency virus (HIV)-infected patients compared with younger HIV-infected patients. DESIGN: Matched (1:2) retrospective case-control study (1993-1999). SETTING: Duke University Infectious Diseases Clinic. PARTICIPANTS: One hundred one older patients, mean age 56.7 (range 50-79) and 202 younger patients, mean age 32.8 (range 21-39). Patients were matched on baseline CD4+ cell count and date of clinic entry. MEASUREMENTS: The virological and immunological outcomes were viral suppression (HIV ribonucleic acid (RNA) level < or =400 copies/ml) and change in CD4+ cell count. To estimate differences in antiretroviral drug exposure, the percentage of patients on ART overall and by drug class was compared. To assess antiretroviral drug exposure further, the percentage of patients having interruptions in ART was compared. RESULTS: The older and younger groups had similar baseline CD4+ cell counts (332 vs 306 cells/mm3; P =.31) and similar increases in CD4+ cell counts (+3.47 vs +4.60 cells/mm3/month; P =.37) over a mean +/- standard deviation of 2.4 +/- 1.7 years of follow-up. The older group had a higher percentage of patients with current plasma HIV RNA levels less than 400 (46% vs 34%; P =.05). The groups had similar rates of non-nucleoside reverse transcriptase, nucleoside reverse transcriptase, and protease inhibitor use. The older group had fewer interruptions in ART than the younger group (11% vs 26%; P =.01). CONCLUSIONS: Older HIV-infected patients responded well to ART, with a significantly greater percentage achieving a current plasma HIV RNA below detectable limits. Older patients experienced similar increases in CD4+ cell count as younger matched controls. Older patients were less likely to interrupt ART, which suggests better adherence and/or tolerance and may explain the higher rate of HIV RNA suppression.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , Adult , Age Distribution , Aged , Case-Control Studies , Female , Humans , Male , Middle Aged , Retrospective Studies , Reverse Transcriptase Inhibitors/therapeutic use , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...